This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome
Neurotherapeutics Open Access 01 April 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH . Guillain–Barré syndrome following allogeneic bone marrow transplantation. Neurology 1997; 49: 1711–1714.
Rodriguez V, Kuehnle I, Heslop HE, Khan S, Krance RA . Guillain–Barré syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 515–517.
Hughes RA, Cornblath DR . Guillain–Barré syndrome. Lancet 2005; 366: 1653–1666.
Amato AA, Barohn RJ, Sahenk Z, Tutschka PJ, Mendell JR . Polyneuropathy complicating bone marrow and solid organ transplantation. Neurology 1993; 43: 1513–1518.
Bashir RM, Bierman P, McComb R . Inflammatory peripheral neuropathy following high dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 1992; 10: 305–306.
Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251–258.
Nobile-Orazio E . Treatment of dys-immune neuropathies. J Neurol 2005; 252: 385–395.
Patriarca F, Skert C, Sperotto A, Zaja F, Falleti E, Mestroni R et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006; 34: 389–396.
Patchell RA . Neurological complications of organ transplantation. Ann Neurol 1994; 36: 688–703.
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756–762.
Acknowledgements
This study was supported in part by The Marrow Foundation 1K04-01 (KCH) and National Institutes of Health Grant HL070053 (KCH).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ostronoff, F., Perales, MA., Stubblefield, M. et al. Rituximab-responsive Guillain–Barré syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplant 42, 71–72 (2008). https://doi.org/10.1038/bmt.2008.81
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.81
This article is cited by
-
Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome
Neurotherapeutics (2022)
-
Axonal variants of Guillain–Barré syndrome: an update
Journal of Neurology (2021)
-
New Strategies in the Management of Guillain–Barré Syndrome
Clinical Reviews in Allergy & Immunology (2014)
-
Severe Guillain–Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review
Clinical Rheumatology (2013)